Q1 2026 Lupin Ltd Earnings Call Transcript
Key Points
- Lupin Ltd (BOM:500257) reported double-digit growth in both revenues and profitability, with margins improving by 330 basis points year-over-year.
- The US business achieved its highest revenues since fiscal year 2017, driven by the successful launch of Tolvaptan with sole first-to-file exclusivity.
- The company has a strong pipeline in complex product categories, including injectables, respiratory biosimilars, and 505(b)(2) products, targeting brand sales of $150 billion.
- Lupin Ltd (BOM:500257) completed the transfer of its OTC Consumer Healthcare business into a 100% owned subsidiary, allowing strategic flexibility and focus on prescription drugs.
- The company achieved a 17% year-over-year increase in other developed markets, with Europe recording a 28% increase, contributing to 13% of total sales.
- Lupin Ltd (BOM:500257) faced negative impacts on growth rates due to loss of exclusivity on certain unlicensed brands in the diabetes segment.
- There were observations in the FDA 483 issued for Pithampur Unit 2 and Unit 3 sites, which the company needs to address.
- The adjacency businesses, such as diagnostics, are currently loss-making, impacting overall EBITDA by approximately 1%.
- The India business growth was impacted by the lumpy nature of the tender business, affecting overall performance.
- The company anticipates increased R&D expenses, which could temper overall margins despite robust business performance.
Thank you and over to you.
Thank you, Ravi. Hi, friends. I'm very pleased to welcome you to our quarter one fiscal year '26 earnings call. I have, with me here, Nilesh, our Managing Director; and our CFO, Ramesh; and of course, Ravi, online as well. We look forward to sharing with you our highlights for the quarter, as well as outlook for the year ahead.
We are delighted to begin the fiscal year on a very strong note with continued double digit growth in both revenues and profitability. Our margins have shown further improvement, rising by 330 basis points year-over-year even as we increased investment in R&D by 150 basis points during the same period. Looking ahead, we're confident that this growth momentum will continue and reaffirm our EBITDA margin outlook for the fiscal year at 24% to 25%.
The first quarter marked a significant milestone for our US business. We successfully launched Toll Lapin with sole first to file exclusivity, resulting in our highest US
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
